Eli Lilly | LLY - Assets



Eli Lilly reported $100.92B in Assets for its fiscal quarter ending in June of 2025.


Assets Change Date
AbbVie USD 136.17B 1B Mar/2025
Abbott USD 84B 2.55B Jun/2025
ALKERMES USD 2.25B 170.83M Jun/2025
Amgen USD 87.9B 1.47B Jun/2025
AstraZeneca USD 112.42B 6.17B Jun/2025
Baxter International USD 21.3B 4.48B Mar/2025
Biogen USD 28.33B 297.1M Jun/2025
Bristol-Myers Squibb USD 94.68B 2.25B Jun/2025
Drreddys Laboratories INR 519.54B 38.48B Jun/2025
Eli Lilly USD 100.92B 11.53B Jun/2025
Gilead Sciences USD 55.72B 713M Jun/2025
GlaxoSmithKline GBP 59.26B 1.45B Jun/2025
Glaxosmithkline GBP 59.26B 205M Jun/2025
J&J USD 193.67B 13.57B Mar/2025
Medtronic USD 91.68B 1.71B Apr/2025
Merck USD 117.52B 2.4B Jun/2025
Neurocrine Biosciences USD 3.89B 202.1M Jun/2025
Novartis USD 104.4B 4.45B Jun/2025
Novartis USD 104.4B 2.15B Jun/2025
Novo Nordisk 482.15B 7.01B Jun/2025
Perrigo USD 10.09B 334.3M Jun/2025
Pfizer USD 206.1B 1.93B Jun/2025
Prestige Brands USD 3.43B 29.41M Jun/2025
Regeneron Pharmaceuticals USD 38.22B 674M Jun/2025
Roche Holding CHF 101.8B 6.02B Dec/2024
Sanofi 124.96B 6.93B Jun/2025
Sanofi 124.96B 7.84B Jun/2025
United Therapeutics USD 7.91B 164.1M Jun/2025
Zoetis USD 14.48B 381M Jun/2025